SCHEMBL1165508

SCHEMBL1165508

NC(=O)c1c[nH]c2ccccc2c1=O

nearest known ligand 0.77

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.77
ATM Q13315 1/20 0.77
CFTR P13569 6/20 0.60
GPR84 Q9NQS5 1/20 0.59
GABRA1 P14867 1/20 0.57
GABRB2 P47870 1/20 0.57
PBRM1 Q86U86 1/20 0.56
NR4A2 P43354 2/20 0.53
PIM1 P11309 1/20 0.53
PIM3 Q86V86 1/20 0.53
MAPK1 P28482 1/20 0.51
CREBBP Q92793 1/20 0.51
STAT3 P40763 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29450818 1.00 ALDH1A1 (0.77) ALDH1A1ATMCFTRGPR84GABRA1
SCHEMBL117198 0.87 ALDH1A1 (1.00) ALDH1A1ATMGPR84PBRM1NR4A2
SCHEMBL27785298 0.87 ALDH1A1 (1.00) ALDH1A1ATMGPR84PBRM1NR4A2
SCHEMBL29544426 0.87 ALDH1A1 (1.00) ALDH1A1ATMGPR84PBRM1NR4A2
Hydrochloric Acid SCHEMBL28283888 0.85 ALDH1A1 (0.96) ALDH1A1ATMGPR84PBRM1NR4A2
Hydrochloric Acid SCHEMBL28283733 0.85 ALDH1A1 (0.96) ALDH1A1ATMGPR84PBRM1NR4A2
Hydrochloric Acid SCHEMBL7400951 0.85 ALDH1A1 (0.96) ALDH1A1ATMGPR84PBRM1NR4A2
Hydrochloric Acid SCHEMBL29715885 0.85 ALDH1A1 (0.96) ALDH1A1ATMGPR84PBRM1NR4A2
SCHEMBL377150 0.84 CFTR (0.67) ALDH1A1ATMCFTRGPR84GABRA1
SCHEMBL29551347 0.84 CFTR (0.67) ALDH1A1ATMCFTRGPR84GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2819670-B1 PHARMACEUTICAL COMPOSITION AND ADMINISTRATION THEREOF VERTEX PHARMA (US) 2026-05-20 EP claimed
CN-116410180-B 4-Oxo quinoline-3-carboxamide derivative and application thereof 青岛大学 2024-09-10 CN claimed
CN-117673514-A Neutral dispergator and preparation method and application thereof 江苏长能节能新材料科技有限公司 2024-03-08 CN claimed
CN-116410180-A 4-oxo quinoline-3-carboxamide derivative and application thereof 青岛大学 2023-07-11 CN claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US claimed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
CN-108948014-A 1- aryl -4- Oxy-1, the preparation and application of the pyrido heterocycle compound of 4- dihydroquinoline structure 江西科技师范大学 2018-12-07 CN claimed
EP-2509954-A1 4 -OXO- 1H -QUINOLINE- 3 - CARBOXAMIDES AS MODULATORS OF ATP -BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals Incorporated (US) 2012-10-17 EP claimed
WO-2011072241-A1 4 -OXO- IH -QUINOLINE- 3 - CARBOXAMIDES AS MODULATORS OF ATP -BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-16 WO claimed
EP-1140851-A1 4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2001-10-10 EP claimed
EP-1080092-A2 BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION WARNER-LAMBERT COMPANY (US) 2001-03-07 EP claimed
WO-2000040563-A1 4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2000-07-13 WO claimed
WO-1999061444-A2 BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION WARNER-LAMBERT COMPANY (US) 1999-12-02 WO claimed
EP-4648753-A1 COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES Vertex Pharmaceuticals Incorporated (US) 2025-11-19 EP disclosed
US-12458635-B2 Pharmaceutical composition and administrations thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-11-04 US disclosed
WO-2025171098-A1 COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-08-14 WO disclosed
EP-0230143-B1 PHOTODEGRADING AGENT, PHOTODEGRADABLE ETHYLENE POLYMER COMPOSITIONS AND ARTICLES PRODUCED THEREFROM THE DOW CHEMICAL COMPANY (US) 1989-11-15 EP disclosed
US-4835163-A N-alkoxyalkyl derivatives of quinolone carboxamides SANOFI (FR) 1989-05-30 US disclosed
US-4835163-A N-alkoxyalkyl derivatives of quinolone carboxamides SANOFI (FR) 1989-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB ALDH1A1 2722/4885ATM 3749/4885CFTR 386/4885
US-12458635-B2 Pharmaceutical composition and administrations thereof CYP3A5, CYP4B1, CYP3A4 ALDH1A1 629/4885ATM 4854/4885CFTR 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.